GlassScriptPhysician profile
Justin Yeh
NPI 1114376662
$8,721.69
in general payments reported to CMS, 2019-2025
60 companies · $2,173 in 2025
The $2,173 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $783 · 2020: $607 · 2021: $735 · 2022: $1,266 · 2023: $1,771 · 2024: $1,387 · 2025: $2,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,331.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,112.80 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Amgen INC. | $772.30 | 2020-2025 | Evenity, Prolia, Otezla |
| Otsuka America Pharmaceutical, INC. | $761.07 | 2020-2025 | Rexulti |
| Novo Nordisk INC | $722.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $553.86 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $519.57 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Axsome Therapeutics, INC. | $442.11 | 2022-2025 | Auvelity, Symbravo |
| Pfizer INC. | $396.51 | 2019-2025 | |
| Lilly USA, LLC | $280.43 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Janssen Pharmaceuticals, INC | $262.40 | 2020-2025 | Spravato, Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.51 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $196.32 | 2019-2024 | Verquvo, Gardasil 9, Vaxelis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $173.12 | 2023-2025 | Caplyta |
| Allergan, INC. | $170.90 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $166.41 | 2019-2024 | Trintellix |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Yeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.